Gastrointestinal Cancer
New Therapies
Expanding treatment options for diverse neuroendocrine tumors
Community Translations
Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval
New Therapies
Hallmark tumor metabolism becomes a validated therapeutic target
From the Journals
Tc-325 effective for immediate GI tumor bleeding
This powder seems to be more predictably effective in providing initial hemostasis in upper GI tumor bleeding, compared with conventional methods...
From the Journals
Refractory FGFR-altered cholangiocarcinoma responds to FGFR kinase inhibitor
A median progression-free survival of 5.8 months is encouraging in patients with this aggressive cancer, and this targeted therapy warrants...
News
FDA approves first trastuzumab biosimilar
The Food and Drug Administration has approved trastuzumab-dkst (Ogivri) as a biosimilar to trastuzumab (Herceptin) for the treatment of patients...
News
Breakthrough cancer gene assay approved, CMS proposes coverage
FDA approves first breakthrough-designated, next-generation sequencing assay that can detect genetic mutations in 324 genes and two genomic...
From the Journals
Mutations influence prognostic value of tumor location in stage III colon cancer
In patients with BRAF or RAS mutations, DFS was better in right-sided vs. left-sided tumors, while in patients with RAS and BRAF double wild type...
From the Journals
Does incretin therapy increase pancreatic cancer risk?
It is unlikely the drugs actually caused the increase in cancer risk.
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
From the Journals
MMR deficiency testing remains low in colorectal cancer patients
Utilization of mismatch repair deficiency testing is poor among patients with colorectal cancer, and remains particularly low among young adults...